Enfuvirtide is active against HIV type 1 group O

AIDS Research and Human Retroviruses

Volumn 21, Issue 6, 2005, Pages 583-585

  Poveda, Eva ^a   Barreiro, Pablo ^a   Rodés, Berta ^a   Soriano, Vincent ^a,b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; ENFUVIRTIDE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RITONAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; VIRUS RNA;

ADULT; ARTICLE; CASE REPORT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; AMINO ACID SEQUENCE; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME;

EID: 21744456884     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2005.21.583     Document Type: Article

References (13)

1. Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, and Bolognesi D: Enfuvirtide: The first therapy to inhibit the entry of HIV-1 in host CD4 lymphocytes. Nat Rev Drug Discov 2004;3: 215-225.
2. Weiss C: HIV-1 gp41: Mediator effusion and target for inhibition. AIDS Rev 2003;5:214-221.
3. Wild C, Greenwell T, and Matthews T: Synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993;9:1051-1053.
4. Clavel F and Hance A: HIV drug resistance. N Engl J Med 2004;350:1023-1035.
5. Poveda E, Rodés B, Labernardière JL, Benito JM, Toro C, González-Lahoz J, et al.: Evolution of genotypic and phenotypic resistance to enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J Med Virol 2004;74:21-28.
6. Lalezari J, Henry K, O'Herarn M, Montaner J, Piliero P, Trottier B, et al.: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-2185.
7. Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, et al.: Efficacy of Enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348: 2186-2195.
8. Greenberg M and Cammack N: Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 2004;54:333-340.
9. Poveda E, Rodés B, Toro C, and Soriano V: Are fusion inhibitors active against all HIV variants? AIDS Res Hum Retroviruses 2004;20:347-348.
10. Labernardiere JL, Lebel-Binay S, Faudon JL, Holguin A, Soriano V, and Cheret A: Tropism determination and performance of Phenoscript HIV-1 entry inhibitor assay. Antiviral Ther 2004; 9(Suppl.):141.
11. Witvrouw M, Pannecouque C, Switzer W, Folks T, De Clercq E, and Heneine W: Susceptibility of HIV-2, SIV, and SIHV to various anti-HIV-1 compounds: Implications for treatment and post-exposure prophylaxis. Antiviral Ther 2004;9:57-65.
12. De Mendoza C, Lu W, Machuca A, Sainz M, Castilla J, and Soriano V: Monitoring the response to antiretroviral therapy in HIV-1 group O infected patients using two new RT-PCR assays. J Med Virol 2001;64:217-222.
13. Thompson J, Higgins D. and Gibson T: CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673-4680.